Board of Directors

Chairman of the Board since 2018. 

MBA, CPA. He served as a Board Member in BioInvent between 2016– 2017. He has held senior executive and board positions at European and US based biotech companies. He held senior executive positions at royal Boskalis NV, GE Capital and Continental Canada Company and has been a consultant with McKinsey and an auditor with Price Waterhouse New York. Born 1958.

Other board appointments: Board member in Zealand Pharma A/S, Basilea International AG and Pharming Group NV. Director in AI Global Investments (Netherlands) PCC Ltd.

Shareholding: 33,538
 

Member of the Board since 2022. 

BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University. Previous Research Associate at the New York University School of Medicine. Currently Managing Director, Therapeutics at Redmile Group, LLC. Born 1990.

Other board appointments: Hansa Biopharma AB, Redx Pharma Plc and Sensorion SA. 

Shareholding: -
 

Member of the Board since 2023. 

MSc in Chemical biology. Elin has worked at the university (KTH) and pharma and biotech industry since 2012 and has experience in antibody discovery and high-throughput analysis. Born 1985.

Other board appointments: -

Shareholding: 92 (affiliated holdings)

Conditional Employee Options: Option program 2023/2025: 2,549; Option program 2024/2026: 1,781; Option program 2025/2027: 1,283

Member of the Board since 2026. 

Master’s degree in international management from the Thunderbird School of Global Management and a bachelor's degree Magna Cum Laude in International Relations from Wheaton College. Completed Part I of the CEDEP International General Management Program at INSEAD. More than 35 years of leadership experience across large public enterprises and venture-backed biotechs, with multiple successful exits. Kate has held senior roles including Interim CEO and President of Ambrx Biopharma, as well as senior leadership positions at 83bar LLC, Radius Health, Bristol Myers Squibb, Pfizer/Wyeth, and Intel, working in the U.S., China, Africa, and globally. Kate is an active speaker across multiple industry forums. Born 1968.

Other board appointments: Chair of the Board of Clue by Biowink. Board member in Mid-Atlantic Diamond Ventures.

Shareholding: - 

Member of the Board since 2022. 

PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford. Currently General Partner at Forbion. Prior experience with Apposite Capital and Novo Holdings. Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Capstan (acquired by Abbvie), Inversago Pharma (acquired by Novo Nordisk), Lava Therapeutics (LVTX), Numab (asset spin-out Yellow Jersey acquired by J&J), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Born 1975.

Other board appointments: Board member in Maplight Therapeutics (MPLT), Sparrow Pharma, F2G and Noema Pharma, board observer in Numab Therapeutics.

Shareholding: -
 

Member of the Board since 2018.

Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.

Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB, and Aptose Inc. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as Pureos BioVentures 

Shareholding: 66,000
 

Member of the Board since 2025.

Tomas has worked in IT Management since 2007 at companies in manufacturing, medical distribution, and pharma. Born in 1981.

Other board appointments: -

Shareholding: 1,240

Conditional Employee Options: Option program 2023/2025: 4,399. Option program 2024/2026: 2,749; Option program 2025/2027: 1,283

Member of the Board since 2026.

MBA from the MIT Sloan School of Management and a BA in Economics & Psychology from Williams College. More than 25 years of global public and private equity experience. He spent more than two decades at Viking Global Investors, where he held roles including Healthcare Analyst, Portfolio Manager, Senior Portfolio Manager, and Team Leader. He also served on Viking's Investment Steering Committee, Management Committee and the Viking Foundation Board. Earlier in his career, he focused on biotechnology investments at Putnam Investments. Born 1977. 

Other board appointments: -

Shareholding:  50,000